Revised SPCs: Hyrimoz (adalimumab) 20 mg solution for injection in pre-filled syringe or pen – all strengths and products

SPC revised to include Kaposi’s sarcoma (a rare cancer related to infection with human herpes virus 8), which most commonly appears as purple lesions on the skin, as an adverse effect of treatment of unknown frequency.

Source:

electronic Medicines compendium